$MEIP
MEI Pharma, Inc.

2019 Q2 Form 10-Q Financial Statement

#000119312519142945 Filed on May 09, 2019

View on sec.gov

Income Statement

Concept 2019 Q2 2019 Q1 2018 Q1
Revenue $1.129M $1.249M $433.0K
YoY Change 106.02% 188.45% -90.39%
Cost Of Revenue $1.100M $1.163M $930.0K
YoY Change -0.9% 25.05% -18.92%
Gross Profit $30.00K $86.00K -$497.0K
YoY Change -105.36% -117.3% -114.8%
Gross Profit Margin 2.66% 6.89% -114.78%
Selling, General & Admin $3.740M $3.630M $2.490M
YoY Change 52.03% 45.78% 15.81%
% of Gross Profit 12466.67% 4220.93%
Research & Development $8.030M $9.071M $3.071M
YoY Change 80.04% 195.38% 63.7%
% of Gross Profit 26766.67% 10547.67%
Depreciation & Amortization $30.00K $20.00K $10.00K
YoY Change 200.0% 100.0% 0.0%
% of Gross Profit 100.0% 23.26%
Operating Expenses $11.78M $9.071M $3.071M
YoY Change 70.48% 195.38% 63.7%
Operating Profit -$11.75M -$12.62M -$6.054M
YoY Change 57.3% 108.39% 803.58%
Interest Expense $14.80M -$4.740M $110.0K
YoY Change -225.64% -4409.09% 57.14%
% of Operating Profit
Other Income/Expense, Net $14.36M -$5.200M
YoY Change -247.89%
Pretax Income $3.050M -$17.36M -$5.950M
YoY Change -115.84% 191.76% 891.67%
Income Tax $0.00 $0.00 $0.00
% Of Pretax Income 0.0%
Net Earnings $3.052M -$17.35M -$5.948M
YoY Change -115.85% 191.76% 888.04%
Net Earnings / Revenue 270.33% -1389.43% -1373.67%
Basic Earnings Per Share $0.04 -$0.24 -$0.16
Diluted Earnings Per Share -$0.15 -$0.24 -$0.16
COMMON SHARES
Basic Shares Outstanding 71.29M 71.20M 37.45M
Diluted Shares Outstanding 71.20M 37.45M

Balance Sheet

Concept 2019 Q2 2019 Q1 2018 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $74.50M $82.30M $36.20M
YoY Change -27.46% 127.35% -36.27%
Cash & Equivalents $9.590M $7.426M $6.198M
Short-Term Investments $64.90M $74.90M $30.00M
Other Short-Term Assets $2.400M $3.200M $900.0K
YoY Change 50.0% 255.56% -67.86%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $82.20M $85.44M $37.06M
YoY Change -21.21% 130.58% -37.74%
LONG-TERM ASSETS
Property, Plant & Equipment $204.0K $213.0K $36.00K
YoY Change 537.5% 491.67% 2.86%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $465.0K $483.0K $341.0K
YoY Change 41.77% 41.64% -9.07%
TOTAL ASSETS
Total Short-Term Assets $82.20M $85.44M $37.06M
Total Long-Term Assets $465.0K $483.0K $341.0K
Total Assets $82.66M $85.93M $37.40M
YoY Change -21.02% 129.77% -37.56%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $4.787M $1.969M $1.259M
YoY Change 31.4% 56.39% 420.25%
Accrued Expenses $4.559M $5.685M $2.382M
YoY Change 31.99% 138.66% -35.81%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $14.30M $11.85M $4.484M
YoY Change 81.37% 164.3% -10.12%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $20.40M $36.20M
YoY Change -55.94%
Total Long-Term Liabilities $20.40M $36.20M $0.00
YoY Change -55.94%
TOTAL LIABILITIES
Total Short-Term Liabilities $14.30M $11.85M $4.484M
Total Long-Term Liabilities $20.40M $36.20M $0.00
Total Liabilities $34.73M $48.04M $4.500M
YoY Change -35.91% 967.64% -10.0%
SHAREHOLDERS EQUITY
Retained Earnings -$231.2M -$234.3M -$195.1M
YoY Change 7.84% 20.05% 14.8%
Common Stock $279.1M $272.2M $228.1M
YoY Change 5.4% 19.33% 1.41%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $47.93M $37.88M $32.91M
YoY Change
Total Liabilities & Shareholders Equity $82.66M $85.93M $37.40M
YoY Change -21.02% 129.77% -37.56%

Cashflow Statement

Concept 2019 Q2 2019 Q1 2018 Q1
OPERATING ACTIVITIES
Net Income $3.052M -$17.35M -$5.948M
YoY Change -115.85% 191.76% 888.04%
Depreciation, Depletion And Amortization $30.00K $20.00K $10.00K
YoY Change 200.0% 100.0% 0.0%
Cash From Operating Activities -$8.060M -$11.34M -$6.240M
YoY Change 114.93% 81.73% -490.0%
INVESTING ACTIVITIES
Capital Expenditures -$10.00K -$40.00K $0.00
YoY Change
Acquisitions
YoY Change
Other Investing Activities $9.970M $9.800M $5.090M
YoY Change -116.78% 92.53% -201.39%
Cash From Investing Activities $9.960M $9.760M $5.090M
YoY Change -116.76% 91.75% -201.6%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 280.0K 250.0K 0.000
YoY Change -99.6%
NET CHANGE
Cash From Operating Activities -8.060M -11.34M -6.240M
Cash From Investing Activities 9.960M 9.760M 5.090M
Cash From Financing Activities 280.0K 250.0K 0.000
Net Change In Cash 2.180M -1.330M -1.150M
YoY Change -69.34% 15.65% -66.28%
FREE CASH FLOW
Cash From Operating Activities -$8.060M -$11.34M -$6.240M
Capital Expenditures -$10.00K -$40.00K $0.00
Free Cash Flow -$8.050M -$11.30M -$6.240M
YoY Change 114.67% 81.09% -490.0%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2019Q1 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
270000
CY2018Q2 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
296000
CY2019Q1 us-gaap Assets
Assets
85926000
CY2018Q2 us-gaap Assets
Assets
104657000
CY2019Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
213000
CY2018Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
32000
CY2019Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
7426000
CY2018Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
13309000
CY2019Q1 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
82290000
CY2018Q2 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
102743000
CY2019Q1 us-gaap Short Term Investments
ShortTermInvestments
74864000
CY2018Q2 us-gaap Short Term Investments
ShortTermInvestments
89434000
CY2019Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3153000
CY2018Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1586000
CY2019Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
1969000
CY2018Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
3643000
CY2019Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
5685000
CY2018Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3454000
CY2019Q1 us-gaap Assets Current
AssetsCurrent
85443000
CY2018Q2 us-gaap Assets Current
AssetsCurrent
104329000
CY2019Q1 us-gaap Warrants Not Settleable In Cash Fair Value Disclosure
WarrantsNotSettleableInCashFairValueDisclosure
31971000
CY2018Q2 us-gaap Warrants Not Settleable In Cash Fair Value Disclosure
WarrantsNotSettleableInCashFairValueDisclosure
46313000
CY2019Q1 us-gaap Liabilities
Liabilities
48044000
CY2018Q2 us-gaap Liabilities
Liabilities
54198000
CY2019Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
85926000
CY2018Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
104657000
CY2019Q1 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
4197000
CY2018Q2 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
788000
CY2019Q1 us-gaap Liabilities Current
LiabilitiesCurrent
11851000
CY2018Q2 us-gaap Liabilities Current
LiabilitiesCurrent
7885000
CY2019Q1 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
272153000
CY2018Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
264858000
CY2019Q1 us-gaap Preferred Stock Value
PreferredStockValue
CY2018Q2 us-gaap Preferred Stock Value
PreferredStockValue
CY2019Q1 us-gaap Common Stock Value
CommonStockValue
0
CY2018Q2 us-gaap Common Stock Value
CommonStockValue
0
CY2019Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-234271000
CY2018Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-214399000
CY2019Q1 us-gaap Stockholders Equity
StockholdersEquity
37882000
CY2018Q2 us-gaap Stockholders Equity
StockholdersEquity
50459000
CY2019Q1 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
1163000
CY2018Q1 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
930000
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
3161000
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
2276000
CY2019Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
9071000
CY2018Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3071000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
24268000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
12579000
CY2019Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3631000
CY2018Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2486000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
10853000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
7332000
CY2019Q1 us-gaap Costs And Expenses
CostsAndExpenses
13865000
CY2018Q1 us-gaap Costs And Expenses
CostsAndExpenses
6487000
us-gaap Costs And Expenses
CostsAndExpenses
38282000
us-gaap Costs And Expenses
CostsAndExpenses
22187000
CY2019Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-17355000
CY2018Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-5948000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-19872000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-20815000
CY2019Q1 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-17355000
CY2018Q1 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-5948000
CY2019Q1 us-gaap Revenues
Revenues
1249000
CY2018Q1 us-gaap Revenues
Revenues
433000
us-gaap Revenues
Revenues
3785000
us-gaap Revenues
Revenues
1074000
CY2019Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-12616000
CY2018Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-6054000
us-gaap Operating Income Loss
OperatingIncomeLoss
-34497000
us-gaap Operating Income Loss
OperatingIncomeLoss
-21113000
CY2019Q1 us-gaap Fair Value Liabilities Measured On Recurring Basis Change In Unrealized Gain Loss
FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss
-5201000
us-gaap Fair Value Liabilities Measured On Recurring Basis Change In Unrealized Gain Loss
FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss
13274000
CY2019Q1 us-gaap Investment Income Interest And Dividend
InvestmentIncomeInterestAndDividend
462000
CY2018Q1 us-gaap Investment Income Interest And Dividend
InvestmentIncomeInterestAndDividend
106000
us-gaap Investment Income Interest And Dividend
InvestmentIncomeInterestAndDividend
1352000
us-gaap Investment Income Interest And Dividend
InvestmentIncomeInterestAndDividend
299000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1000
CY2019Q1 us-gaap Net Income Loss
NetIncomeLoss
-17355000
CY2018Q1 us-gaap Net Income Loss
NetIncomeLoss
-5948000
us-gaap Net Income Loss
NetIncomeLoss
-19872000
us-gaap Net Income Loss
NetIncomeLoss
-20815000
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-43309000
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-20815000
CY2019Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.24
CY2018Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.16
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.28
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.56
CY2019Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.24
CY2018Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.16
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.60
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.56
CY2019Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
71200000
CY2018Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
37449000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
71069000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
37369000
CY2019Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
71200000
CY2018Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
37449000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
72011000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
37369000
us-gaap Share Based Compensation
ShareBasedCompensation
5114000
us-gaap Share Based Compensation
ShareBasedCompensation
2468000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
52000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
40000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1567000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-904000
us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
-1674000
us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
674000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
2231000
CY2019Q1 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
8419000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-670000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
7631000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-153000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
207000
us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
39756000
us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
29937000
us-gaap Proceeds From Maturities Prepayments And Calls Of Shortterm Investments
ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments
54326000
us-gaap Proceeds From Maturities Prepayments And Calls Of Shortterm Investments
ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments
45040000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
14363000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
15103000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
319000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
189000
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
1118000
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
324000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
1113000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
189000
CY2019Q1 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
4222000
CY2018Q2 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
0
us-gaap Profit Loss
ProfitLoss
-19872000
us-gaap Profit Loss
ProfitLoss
-20815000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-21359000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-17552000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-5883000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-2260000
CY2018Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
13309000
CY2017Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
8458000
CY2019Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
7426000
CY2018Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
6198000
CY2019Q1 us-gaap Revenues
Revenues
1249000
CY2018Q1 us-gaap Revenues
Revenues
433000
us-gaap Revenues
Revenues
3785000
CY2019Q1 us-gaap Revenue Remaining Performance Obligation
RevenueRemainingPerformanceObligation
8400000
CY2018Q2 meip Accounts Receivable Net Beginning Balance
AccountsReceivableNetBeginningBalance
82000
us-gaap Increase Decrease In Receivables
IncreaseDecreaseInReceivables
51000
CY2019Q1 meip Accounts Receivable Net Ending Balance
AccountsReceivableNetEndingBalance
133000
CY2018Q2 us-gaap Contract With Customer Asset Net Current
ContractWithCustomerAssetNetCurrent
312000
us-gaap Increase Decrease In Contract With Customer Asset
IncreaseDecreaseInContractWithCustomerAsset
85000
CY2019Q1 us-gaap Contract With Customer Asset Net Current
ContractWithCustomerAssetNetCurrent
397000
CY2018Q2 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
788000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
7631000
meip Agreement Termination Notice Period
AgreementTerminationNoticePeriod
P90D
meip Percentage Of Purchases From Major Suppliers
PercentageOfPurchasesFromMajorSuppliers
1.00
CY2018Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-5948000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-19872000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-20815000
CY2018Q1 us-gaap Fair Value Liabilities Measured On Recurring Basis Change In Unrealized Gain Loss
FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss
0
us-gaap Fair Value Liabilities Measured On Recurring Basis Change In Unrealized Gain Loss
FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss
0
CY2018Q1 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-5948000
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-43309000
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-20815000
CY2019Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
24207000
CY2018Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5913000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
7912000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
18819000
CY2019Q1 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
0
us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
942000
CY2018Q1 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
0
us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
0
CY2019Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
71200000
CY2018Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
37449000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
37369000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
72011000
CY2019Q1 us-gaap Weighted Average Number Of Shares Issued Basic
WeightedAverageNumberOfSharesIssuedBasic
71200000
CY2018Q1 us-gaap Weighted Average Number Of Shares Issued Basic
WeightedAverageNumberOfSharesIssuedBasic
37052000
us-gaap Weighted Average Number Of Shares Issued Basic
WeightedAverageNumberOfSharesIssuedBasic
36970000
us-gaap Weighted Average Number Of Shares Issued Basic
WeightedAverageNumberOfSharesIssuedBasic
71069000
CY2019Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
71200000
CY2018Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
37449000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
37369000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
71069000
CY2018Q1 us-gaap Weighted Average Number Of Shares Restricted Stock
WeightedAverageNumberOfSharesRestrictedStock
397000
us-gaap Weighted Average Number Of Shares Restricted Stock
WeightedAverageNumberOfSharesRestrictedStock
399000
CY2019Q1 us-gaap Weighted Average Number Of Shares Restricted Stock
WeightedAverageNumberOfSharesRestrictedStock
0
us-gaap Weighted Average Number Of Shares Restricted Stock
WeightedAverageNumberOfSharesRestrictedStock
0
CY2019Q1 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
46000
CY2018Q3 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
21000
CY2019Q1 meip Lease Arrangement Rent Area
LeaseArrangementRentArea
13700
CY2018Q3 meip Lease Arrangement Rent Area
LeaseArrangementRentArea
7000
CY2019Q1 meip Milestone Payments Maximum Amount
MilestonePaymentsMaximumAmount
74500000
CY2019Q1 meip Percentage Of Purchases From Major Suppliers
PercentageOfPurchasesFromMajorSuppliers
1.00
CY2019Q1 meip Shelf Registration Statement Value
ShelfRegistrationStatementValue
150000000
CY2018Q2 us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
70200000
CY2018Q2 us-gaap Warrants Not Settleable In Cash Fair Value Disclosure
WarrantsNotSettleableInCashFairValueDisclosure
36600000
meip Exercise Of Warrants For Common Stock
ExerciseOfWarrantsForCommonStock
440043
CY2019Q1 us-gaap Class Of Warrant Or Right Number Of Securities Called By Each Warrant Or Right
ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
16061602
us-gaap Revenues
Revenues
1074000
meip Revenue Performance Obligation Amount
RevenuePerformanceObligationAmount
1100000
us-gaap Contract With Customer Performance Obligation Satisfied In Previous Period
ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod
4200000
meip Additional Recognition Of Deferred Revenue
AdditionalRecognitionOfDeferredRevenue
4200000
CY2019Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2019Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
100
CY2018Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2018Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
100
CY2019Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
226000
CY2019Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
71281
CY2019Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
70406
CY2018Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
226000
CY2018Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
71281
CY2018Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
70406
CY2019Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2018Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2019Q1 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
188552
us-gaap Use Of Estimates
UseOfEstimates
<div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 18pt;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Use of Estimates </div></div></div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 6pt; text-indent: 0.8in;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and disclosures made in the accompanying notes to the financial statements. We use estimates that affect the reported amounts (including assets, liabilities, revenues and expenses) and related disclosures. Actual results could materially differ from those estimates. </div></div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2019Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y7M6D
CY2019Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
4632560
CY2019Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
3718739
CY2019Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
3.02
CY2019Q1 us-gaap Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation
WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation
0
us-gaap Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation
WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation
0
CY2018Q1 us-gaap Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation
WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation
0
us-gaap Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation
WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation
0
CY2019Q1 meip Lease Expiration Month And Year
LeaseExpirationMonthAndYear
2020-05
CY2019Q1 us-gaap Share Based Compensation
ShareBasedCompensation
1514000
CY2018Q1 us-gaap Share Based Compensation
ShareBasedCompensation
770000
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
6281615
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
3.08
CY2019Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
2489250
CY2019Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
4.07
CY2019Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
1.69
CY2019Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P6Y1M6D
CY2019Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
3428724
CY2019Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
311473
CY2019Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
3.16
CY2019Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
233854
CY2019Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
7.43
CY2019Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
8036986
CY2019Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
3.29
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.028
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.021
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.00
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.849
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.957
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.00
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
2.95
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
2.10
CY2019Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
6000000
CY2019Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P1Y8M12D
CY2017Q2 us-gaap Stockholders Equity
StockholdersEquity
-174331000
CY2019Q1 meip Fair Value Assumptions Exercise Price Warrants Issued
FairValueAssumptionsExercisePriceWarrantsIssued
3.07
CY2018Q2 meip Fair Value Assumptions Exercise Price Warrants Issued
FairValueAssumptionsExercisePriceWarrantsIssued
3.94
CY2019Q1 meip Number Of Clinical Stage Candidates
NumberOfClinicalStageCandidates
4
CY2019Q1 meip Number Of Candidate In An Ongoing Global Registration Trial
NumberOfCandidateInAnOngoingGlobalRegistrationTrial
1
CY2018Q4 meip Manufacturing Rights Commencing Period
ManufacturingRightsCommencingPeriod
P3Y
CY2019Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2018Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2019Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00000002
CY2018Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00000002
CY2017Q3 us-gaap Net Income Loss
NetIncomeLoss
-8788000
CY2017Q3 meip Stock Issued During The Period Value Milestone Payment
StockIssuedDuringThePeriodValueMilestonePayment
500000
CY2017Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
20000
CY2017Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
996000
CY2017Q3 us-gaap Stockholders Equity
StockholdersEquity
43566000
CY2017Q4 us-gaap Net Income Loss
NetIncomeLoss
-6079000
CY2017Q4 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
169000
CY2017Q4 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
702000
CY2017Q4 us-gaap Stockholders Equity
StockholdersEquity
38358000
CY2018Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
770000
CY2018Q1 us-gaap Stockholders Equity
StockholdersEquity
32913000
CY2018Q1 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
-267000
CY2018Q3 us-gaap Net Income Loss
NetIncomeLoss
-14542000
CY2018Q3 meip Stockissuedduringperiodvaluestockwarrantsexercised
Stockissuedduringperiodvaluestockwarrantsexercised
2186000
CY2018Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
43000
CY2018Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1937000
CY2018Q3 us-gaap Stockholders Equity
StockholdersEquity
39759000
CY2018Q4 us-gaap Net Income Loss
NetIncomeLoss
12025000
CY2018Q4 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
24000
CY2018Q4 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1663000
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
53471000
CY2019Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
252000
CY2019Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1514000
dei Document Type
DocumentType
10-Q
dei Amendment Flag
AmendmentFlag
false
dei Document Period End Date
DocumentPeriodEndDate
2019-03-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2019
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Entity Registrant Name
EntityRegistrantName
MEI Pharma, Inc.
dei Entity Central Index Key
EntityCentralIndexKey
0001262104
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--06-30
dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
dei Trading Symbol
TradingSymbol
MEIP
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Small Business
EntitySmallBusiness
true
CY2019Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
71290460

Files In Submission

Name View Source Status
0001193125-19-142945-index-headers.html Edgar Link pending
0001193125-19-142945-index.html Edgar Link pending
0001193125-19-142945.txt Edgar Link pending
0001193125-19-142945-xbrl.zip Edgar Link pending
d739656d10q.htm Edgar Link pending
d739656dex311.htm Edgar Link pending
d739656dex312.htm Edgar Link pending
d739656dex321.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
g739656g55z44.jpg Edgar Link pending
meip-20190331.xml Edgar Link completed
meip-20190331.xsd Edgar Link pending
meip-20190331_cal.xml Edgar Link unprocessable
meip-20190331_def.xml Edgar Link unprocessable
meip-20190331_lab.xml Edgar Link unprocessable
meip-20190331_pre.xml Edgar Link unprocessable
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending